Company intelligence / Profile preview

Hain Lifescience

Nehren, Baden-Württemberg, Germany

Ownership: Private
Employees: ~100
Development stage: Other

Overview

Hain Lifescience offers a broad range of CE/IVD molecular diagnostic products for infectious disease, genetic and syndromic panel testing, including globally recommended and WHO-endorsed assays for tuberculosis drug resistance. Its technologies are established in clinical labs and supported by robust performance data for rapid detection and differentiation of multiple pathogens and key genetic markers.

Therapeutic areas: Infectious DiseasesRare Diseases
Modalities: Molecular diagnosticPCR-based assayMultiplex PCRReal-time PCR
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Hain Lifescience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hain Lifescience.

Explore the full profile